Bundle payment model analysis of emerging breast cancer screening

March 04, 2019

Bundled payments have been touted as mechanisms to optimize quality and costs. A prior feasibility study evaluating bundled payments for screening mammography episodes predated widespread adoption of digital breast tomosynthesis (DBT). A new study, published online in the Journal of the American College of Radiology (JACR), explores an episodic bundled payment model for breast cancer screening that reflects the emerging widespread adoption of DBT.

"Bundled episodic payments are an important type of alternative payment model (APM) that incentivize cost savings within discrete episodes of care," said the new study's lead author Margaret Fleming, assistant professor of radiology and imaging sciences at Emory University. "More recent interest has been expressed in developing outpatient imaging-based cancer screening episodes."

In the earlier 2016 JACR study, Hughes and colleagues explored the feasibility of screening mammography as a potential bundle payment model. The claims data they used predated the implementation of Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding System (HCPCS) codes to report digital breast tomosynthesis (DBT), and thus did not consider the potential impact of this emerging service on their proposed bundled prices. Since receiving approval from the US FDA in 2011, DBT has gained widespread acceptance.

In Fleming's large academic health system, screening mammography is performed at outpatient sites affiliated with four separate hospitals, which have all now since adopted DBT as part of routine screening. For this analysis, Fleming and colleagues focused on the two large hospitals that had no DBT capabilities in 2013, but which subsequently performed DBT routinely as part of their screening examinations in 2015 (2014 was a transition year for both).

"Excluding DBT, Medicare-normalized bundled prices for traditional breast imaging 364 days downstream to screening mammography are extremely similar pre- and post-DBT implementation- $182.86 in 2013; $182.68 in 2015," stated study senior author Richard Duszak, MD, FACR, professor and vice chair for health policy and practice in the department of radiology and imaging sciences at Emory University and senior affiliate research fellow at the Neiman Institute. "The addition of DBT increased a DBT-inclusive bundled price by $53.16--an amount lower than the $56.13 Medicare allowable fee for screening DBT but was associated with significantly reduced recall rates 13.0% versus 9.4%." Without or with DBT, screening episode bundled prices remained sensitive to bundle-included services and varied little by patient age, race, or insurance status.

Based on their findings, the authors concluded that non-DBT approaches to bundled payment models for breast cancer screening remain viable as DBT becomes the standard of care, with bundle prices varying little by patient age, race, or insurance status. Higher DBT-inclusive bundled prices, however, highlight the need to explore societal costs more broadly (eg, reduced time away from work from fewer recalls) as bundled payment models evolve.
To obtain a copy of the study or to arrange an interview with a Neiman Institute spokesperson, contact Nichole Gay at (703) 648-1665 or ngay@neimanhpi.org.

Harvey L. Neiman Health Policy Institute

Related Breast Cancer Screening Articles from Brightsurf:

Researchers take issue with study evaluating an AI system for breast cancer screening
In a new perspective piece 'Transparency and reproducibility in artificial intelligence' published this week in the journal Nature, an international group of scientists including CUNY Graduate School of Public Health and Health Policy (CUNY SPH) Associate Professor Levi Waldron raised concerns about the lack of transparency in publication of artificial intelligence algorithms for health applications.

Screening mammography could benefit men at high risk of breast cancer
Selective mammography screening can provide potentially lifesaving early detection of breast cancer in men who are at high risk for the disease, according to a new landmark study.

Bundle payment model analysis of emerging breast cancer screening
Bundled payments have been touted as mechanisms to optimize quality and costs.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

Breast cancer screening does not reduce mortality
Fewer and fewer women die from breast cancer in recent years but, surprisingly, the decline is just as large in the age groups that are not screened.

Is prognosis poor for breast cancer diagnosed after negative screening mammography?
A study of mammography data for more than 300,000 women suggests cases of breast cancer diagnosed after a negative screening mammogram were more likely to be associated with poor prognosis than those cancers diagnosed after a positive screening mammogram.

Making individualized choices about breast cancer screening
The authors note, that despite the fact that the United States Preventive Services Task Force (USPSTF) changed its recommendation in 2009 to mammograms every two years for women aged 50-74 instead of annual mammograms beginning at age 40, there has been little change in US screening practices.

Why are women at high breast cancer risk not having supplemental MRI screening?
Women at high lifetime breast cancer risk might benefit from breast MRI screening in addition to routine mammography, but a new study shows that breast MRI is greatly underutilized even though access is widely available.

Community practices not following guidelines for MRI breast cancer screening
Guidelines are not being followed to ensure that breast cancer screening of high risk women, such as those with a strong family history of breast cancer, includes an additional MRI (magnetic resonance imaging) scan.

Screening has had 'little impact' on falling breast cancer deaths in the Netherlands
Breast screening in the Netherlands seems to have had a marginal effect on breast cancer mortality over the past 24 years, suggests research in The BMJ today.

Read More: Breast Cancer Screening News and Breast Cancer Screening Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.